IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
20 hedge funds and large institutions have $24.8M invested in IO Biotech in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
3.93% less ownership
Funds ownership: 39.81% → 35.88% (-3.9%)
19% less capital invested
Capital invested by funds: $30.7M → $24.8M (-$5.87M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$289K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$132K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$94.4K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$76.4K |
| 5 |
Two Sigma Investments
New York
|
+$37.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.81M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.35M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$368K |
| 4 |
Renaissance Technologies
New York
|
-$106K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$102K |
IOBT Hedge Fund Activity: Q3 2024 in Review
20 of the 6,971 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q3 2024, worth a combined $24.8M — down 19% from $30.7M a quarter earlier.
Fund positioning in IOBT was balanced in Q3 2024: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $289K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.81M sold.
- 20 institutional investors held IO Biotech (IOBT) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $24.8M of IO Biotech stock for Q3 2024, down 19% quarter-over-quarter.
- 5 funds opened new IO Biotech positions in Q3 2024 and 5 closed out, a net change of 0 holders.
- The largest IO Biotech buyer in Q3 2024 was Morgan Stanley, an estimated $289K added.
- The largest IO Biotech seller in Q3 2024 was Armistice Capital, an estimated $1.81M sold.
Based on aggregated 13F filings for Q3 2024.